02157 LEPU BIO-B
- 2.520
- -0.100-3.82%
LEPU BIO-B News
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
【Brokerage Focus】The Pacific Securities initially rated Lepu Biopharma (02157) as "Buy", indicating that the ADC pipeline is about to enter a harvest period.
Jinwu Financial News | The Pacific Securities Research Reports indicate that Lepu Biopharma (02157) is focusing on precision matching for PD-1, creating a diverse and comprehensive combination of combination therapies: with a forward-looking layout around "PD-1 + ADC", the current EGFR ADC and HER2 ADC combined with PD-1 treatment schemes are in the phase II clinical stage; the clinical trials of oncolytic virus CG0070 combined with PD-1 for non-muscle invasive bladder cancer indications are in the preparation stage. The institution stated that Lepu Biopharma's Putri monoclonal antibody was commercialized in 2022 and is continuously expanding new indications through the combination with ADC.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Lepu Biopharma Co., Ltd.'s (HKG:2157) Largest Shareholder, Top Key Executive Zhongjie Pu Sees Holdings Value Fall by 9.6% Following Recent Drop
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotech-B (02157.HK) has signed a CDMO service framework agreement with lepu medical technology.
On November 26, Gleam Hill reported that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, pursuant to which the company and/or its subsidiaries agreed to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
Luoping Biotechnology -B (02157.HK) intends to appoint Ernst & Young as the new auditor.
Gelonghui, November 26 - Lepu Bio-B (02157.HK) announced that PricewaterhouseCoopers has agreed to resign as the company's auditor, effective November 26, 2024. The company intends to appoint Ernst & Young as the new auditor for the 2024 fiscal year, with the term ending at the conclusion of the company's next annual general meeting of shareholders.
Hong Kong stock market anomaly | Some pharmaceutical stocks rise, medical insurance negotiations support innovative drugs. Institutions point out that the sector still has further room for recovery.
Some pharmaceutical stocks rose, as of the deadline, SciClone Pharmaceuticals-B (02171) rose by 33.68% to HK$8.97; Concord Jingrui Pharmaceuticals-B (09966) rose by 10.34% to HK$4.27; LuPu Biotech-B (02157) rose by 7.87% to HK$3.29.
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Lepu Biopharma Cancer Drug's NDA Approved by China's NDMA; Stocks Up 8%
Luoping Biosciences-B (02157.HK): MRG003 for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) has been accepted for new drug application by the National Medical Products Administration and included in priority review.
September 27, Geelonghui - The company LePu Biology-B (02157.HK) announced that it has received the "Acceptance Notice" issued by the China National Medical Products Administration (NMPA). The company's candidate drug MRG003 (an epidermal growth factor receptor (EGFR) targeted antibody-drug conjugate (ADC) candidate drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC))'s new drug application (NDA) has been accepted. MRG003 has also been included in the priority review by the NMPA Center for Drug Evaluation (CDE) ("Priority Review").
Luopu Biology-B (02157): NMPA accepted the drug registration application of MRG003 and included it in the priority review.
Lupe Bio-B (02157) announced that the company has received the issuance from the National Medical Products Administration (NMPA) of china...
Express News | Lepu Biopharma Co Ltd - Acceptance of New Drug Application and Priority- Review Granted by Nmpa to- Mrg003
LEPU BIO-B: 2024 Interim Report
Hong Kong stock abnormal | Livzon Pharmaceutical Group Inc. - B (02157) is now up more than 4%, the injection of Vedolizumab is planned to be included in priority review.
Lepu Medical-B(02157) is now up more than 4%. As of the time of writing, it has increased by 4.44%, reaching 3.06 Hong Kong dollars, with a turnover of 8.1931 million Hong Kong dollars.
HKEX market abnormal movement | Livzon Pharmaceutical Group Inc - Class B (02157) fell more than 3% after performance announcement, with a net loss attributable to shareholders of 192 million yuan in the first half of the year, a year-on-year increase of
LePu Biotechnology-B (02157) fell more than 3% after the performance announcement, as of the time of publication, it fell 3.46%, with a price of HK$2.23 and a turnover of HK$5.6623 million.
Luoping Biological-B (02157) released its interim performance, with a shareholder's attributable loss of 0.192 billion yuan, a year-on-year increase of 35.6%.
Le Pu Biological-B (02157) released its six-month performance as of June 30, 2024, with a revenue of 0.133 billion...
Express News | Lepu Biopharma H1 Adjusted Net Income RMB -192.4 Million
Express News | Lepu Biopharma H1 Revenue RMB 94.8 Million
No Data
